Organogenesis
(NASDAQ) ORGO
Organogenesis Financials at a Glance
Market Cap
$307.45M
Revenue (TTM)
$563.94M
Net Income (TTM)
$37.03M
EPS (TTM)
$0.11
P/E Ratio
21.83
Dividend
$0.00
Beta (Volatility)
1.62 (High)
Dividend
$0.00
Beta (Volatility)
1.62 (High)
Price
$2.38
Volume
756,975
Open
$2.40
Price
$2.38
Volume
756,975
Open
$2.40
Previous Close
$2.39
Daily Range
$2.34 - $2.46
52-Week Range
$2.31 - $7.08
Dividend
$0.00
Beta (Volatility)
1.62 (High)
Price
$2.38
Volume
756,975
Open
$2.40
Previous Close
$2.39
Daily Range
$2.34 - $2.46
52-Week Range
$2.31 - $7.08
ORGO News
ORGO Sales Drop 23%
ORGO: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Organogenesis
Industry
Biotechnology
Sector
Health CareEmployees
854
CEO
Gary S. Gillheeney, Sr., MBA
Website
www.organogenesis.comHeadquarters
Canton, MA 02021, US
ORGO Financials
Key Financial Metrics (TTM)
Gross Margin
74%
Operating Margin
8%
Net Income Margin
7%
Return on Equity
9%
Return on Capital
9%
Return on Assets
6%
Earnings Yield
4.58%
Dividend Yield
0.00%
Payout Ratio
0.51%
Stock Overview
Market Cap
$307.45M
Shares Outstanding
128.64M
Volume
756.98K
Short Interest
0.00%
Avg. Volume
807.69K
Financials (TTM)
Gross Profit
$415.06M
Operating Income
$56.38M
EBITDA
$83.32M
Operating Cash Flow
$10.31M
Capital Expenditure
$14.15M
Free Cash Flow
$24.46M
Cash & ST Invst.
$93.68M
Total Debt
$132.84M
Organogenesis Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$225.61M
+78.1%
Gross Profit
$168.68M
+76.4%
Gross Margin
74.77%
N/A
Market Cap
$307.45M
N/A
Market Cap/Employee
$353.80K
N/A
Employees
869
N/A
Net Income
$43.70M
+469.5%
EBITDA
$72.24M
+393.4%
Quarterly Fundamentals
Net Cash
$39.16M
-142.5%
Accounts Receivable
$217.45M
+97.9%
Inventory
$29.63M
+13.0%
Long Term Debt
$114.20M
+233.9%
Short Term Debt
$18.64M
+104.6%
Return on Assets
6.19%
N/A
Return on Invested Capital
9.35%
N/A
Free Cash Flow
$34.77M
+358.9%
Operating Cash Flow
$39.42M
+260.4%